81
Views
8
CrossRef citations to date
0
Altmetric
Editorial

Designing safe drugs: what to consider?

Pages 707-713 | Published online: 23 Jun 2008
 

Abstract

Toxicity continues to be a primary source of attrition at all stages of drug development. Attention to a few key considerations has the potential to move safety-related attrition earlier, before the expenditure of significant resources on a compound with a low chance of successfully reaching the market. The use of predictive in vitro toxicity assays, early in vivo signal generation studies, and application of new technologies will significantly reduce time spent and money lost owing to failures during development. In addition, more deliberate and informed application of assays for reducing the risk of human-specific toxicity holds promise for improving drug development success rates and reducing late-stage failures and post-approval withdrawals.

Notes

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 99.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,340.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.